期刊
CHIMIA
卷 67, 期 12, 页码 910-915出版社
SWISS CHEMICAL SOC
DOI: 10.2533/chimia.2013.910
关键词
Cyclic peptides; Directed evolution; Peptides; Phage display; Therapeutics
资金
- Swiss National Science Foundation (SNSF) [PP00P3_123524/1]
- National Competence Center for Biomolecular Imaging (NCCBI)
- Swiss National Science Foundation (SNF) [PP00P3_123524] Funding Source: Swiss National Science Foundation (SNF)
Many naturally occurring cyclic peptides or derivatives thereof are used as therapeutics such as the human hormones vasopressin and oxytocin or the antibiotics vancomycin and daptomycin. The success of cyclic peptide therapeutics is based on their ability to bind with high affinity, their good target selectivity and their low toxicity. As nature provides cyclic peptides to only a small number of disease targets, strategies have been developed to generate cyclic peptide ligands with tailored specificity de novo. Our laboratory is specialized on the directed evolution of bicyclic peptide ligands by phage display. In this article, we review our recent work to in vitro evolve bicyclic peptide antagonists, the binding and pharmacokinetic properties of bicyclic peptides, as well as efforts to generate bicyclic peptides for therapeutic application.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据